tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2022 Sep 28;28(11).
doi: 10.3201/eid2811.221043. Online ahead of print.
Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021
James W Lewis, Julie Loughran, Li Deng, Jasmine Varghese, Shauna Clark, Casandra Harrison, Molly Gacetta, John A Jernigan, Katherine E Fleming-Dutra
Abstract
A SARS-CoV-2 P.1 (Gamma) variant outbreak occurred at a skilled nursing facility in Washington, USA, in April 2021. Effectiveness of 2 doses of mRNA vaccines against P.1 infection among residents in this outbreak was 75.0% (95% CI 44.5%-88.7%), similar to effectiveness for other pre-Delta variants among long-term care residents.
Keywords: COVID-19; P.1; SARS-CoV-2; United States; coronavirus disease; long-term care; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine effectiveness; viruses; zoonoses.
. 2022 Sep 28;28(11).
doi: 10.3201/eid2811.221043. Online ahead of print.
Vaccine Effectiveness against SARS-CoV-2 Variant P.1 in Nursing-Facility Residents, Washington, USA, April 2021
James W Lewis, Julie Loughran, Li Deng, Jasmine Varghese, Shauna Clark, Casandra Harrison, Molly Gacetta, John A Jernigan, Katherine E Fleming-Dutra
- PMID: 36170764
- DOI: 10.3201/eid2811.221043
Abstract
A SARS-CoV-2 P.1 (Gamma) variant outbreak occurred at a skilled nursing facility in Washington, USA, in April 2021. Effectiveness of 2 doses of mRNA vaccines against P.1 infection among residents in this outbreak was 75.0% (95% CI 44.5%-88.7%), similar to effectiveness for other pre-Delta variants among long-term care residents.
Keywords: COVID-19; P.1; SARS-CoV-2; United States; coronavirus disease; long-term care; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccine effectiveness; viruses; zoonoses.